In preeclampsia, biofeedback-assisted relaxation outperformed reference treatments in two independent randomised trials: better blood-pressure control, less proteinuria and a lower antihypertensive dose. Obstetric monitoring obviously remains the priority.
Updated :
What the research shows
Biofeedback
Assisted relaxation (electrodermal, thermal, HRV) alongside obstetric care — preeclampsia and pregnancy-induced hypertension
AAPB5Efficacious and specificNeuroLogic5Efficacious and specificsame vs AAPB
Level 5 maintained. Two independent randomised trials showed biofeedback-assisted relaxation to be superior to bona fide alternative treatments. Somers 1989: 45 women at 30-36 weeks with mild pregnancy-induced hypertension randomised to bed rest alone, compliance-enhancement training, or a biobehavioural package adding blood-pressure monitoring and thermal biofeedback-assisted relaxation to the same four hours of training — the biobehavioural group raised hand temperature and reduced mean arterial pressure below both comparators, and only 9 of 15 exceeded 95 mm Hg at the final prenatal visit against 14 of 15 in each other arm. El-Kosery, Abd-El Raoof & Farouk 2005: 35 women randomised to galvanic-skin-response biofeedback-assisted relaxation three times weekly for 6 weeks plus methyldopa, or methyldopa alone — greater reductions in systolic and diastolic pressure, heart rate, proteinuria and methyldopa dose, while the control group's methyldopa dose rose. Little 1984 (n = 50, sequential allocation) found both relaxation and skin-conductance biofeedback superior to treatment as usual on hospitalisation frequency and length, diastolic pressure and proteinuria. No 2022-2026 publication on biofeedback in preeclampsia passed screening.
In short
Clinical reading
AAPB Level 5, maintained by NeuroLogic: two independent RCTs showed superiority over bona fide treatments — methyldopa alone (El-Kosery 2005) and compliance-enhancement training with matched contact time (Somers 1989). Three RCTs in total, plus a pre/post prevention study and a historically controlled HRV biofeedback study (Cullins 2013).
Protocols
Relaxation assisted by electrodermal, thermal or HRV biofeedback (breathing at 4.5-7 breaths per minute), alongside obstetric care, with home blood-pressure monitoring and daily practice.
Limits
Small and dated literature (the most recent trial is from 2005), samples of 35 to 50 women, no assessor-blind trial; protocols vary by modality and the only HRV biofeedback study did not change blood pressure. No 2022-2026 publication.
Study base
Three RCTs, one multi-group study with a historical control, one pre/post study. 2022-2026 base: no publication indexed in the archive.
Brendan's perspective
Level 5 maintained. The comparators here are genuinely active — methyldopa alone (El-Kosery 2005), compliance-enhancement training with matched contact time (Somers 1989), bed rest under full obstetric monitoring — and the outcomes are objective: blood pressure, proteinuria, hospitalisation. That is exactly what a level 5 should reflect. But the level rates the comparison, not the size or the recency of the literature: three trials, 35 to 50 women, no blinded assessment, sequential allocation in Little 1984, and nothing published since 2005. Hypertensive pregnancy is not something I manage, and obstetric follow-up comes before anything else. What remains deployable is resonance-frequency breathing with HRV feedback as an adjunct, bearing in mind that the one HRV study here, Cullins 2013 with a historical control, did not move blood pressure. The honest line: no trial has shown improved perinatal outcomes.
Cullins et al. (2013) An exploratory analysis of the utility of adding cardiorespiratory biofeedback in the standard care of pregnancy-induced hypertension doi:10.1007/s10484-013-9219-4
